Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

The Danish biotech’s recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed ...

The obesity drug market has experienced a seismic shift in recent years, with Novo Nordisk's (NOV: N) Wegovy (semaglutide) ...

GCA is an autoimmune condition, predominantly affecting individuals over 50, with the highest incidence between 70 and 80 ...

While it is understood that the drugs have also proven to be safe and effective for thousands, the negative issues have led ...

Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel ...

At the recent ATTD 2025 meeting, participants discussed recent progress and remaining challenges in developing a fully closed ...

Danish biotech Gubra (CPSE: GUBRA) saw its share gains more than 8% to 448.00 kroner, after it announced positive results from the single ascending dose (SAD) Phase I clinical trial with the ...

Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing study, which is evaluating the safety and efficacy of the oral formulation ...